Cytoreductive surgery in the era of targeted molecular therapy

Arun Z. Thomas; Mehrad Adibi; Leonardo D. Borregales; Jose A. Karam; Christopher G. Wood

doi:10.3978/j.issn.2223-4683.2015.04.09

Cytoreductive surgery in the era of targeted molecular therapy

Arun Z. Thomas, Mehrad Adibi, Leonardo D. Borregales, Jose A. Karam, Christopher G. Wood

Urology

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cell carcinoma (mRCC) in the immunotherapy era. With the advent of targeted molecular therapy (TMT) for the treatment of mRCC, the routine use of CN has been questioned. Up to date evidence continues to suggest that CN remains an integral part of treatment in appropriately selected patients. This review details the original context in which the efficacy of CN was established and rationale for the continued use of cytoreductive surgery in the era of TMT.

Original language	English (US)
Pages (from-to)	301-309
Number of pages	9
Journal	Translational Andrology and Urology
Volume	4
Issue number	3
DOIs	https://doi.org/10.3978/j.issn.2223-4683.2015.04.09
State	Published - 2015

Keywords

Cytoreductive nephrectomy (CN)
Kidney cancer
Targeted molecular therapy (TMT)
Tyrosine kinase inhibitors (TKI)

ASJC Scopus subject areas

Reproductive Medicine
Urology

Access to Document

10.3978/j.issn.2223-4683.2015.04.09

Cite this

@article{3259d53c2b514c55b9ffc697274f4683,

title = "Cytoreductive surgery in the era of targeted molecular therapy",

abstract = "Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cell carcinoma (mRCC) in the immunotherapy era. With the advent of targeted molecular therapy (TMT) for the treatment of mRCC, the routine use of CN has been questioned. Up to date evidence continues to suggest that CN remains an integral part of treatment in appropriately selected patients. This review details the original context in which the efficacy of CN was established and rationale for the continued use of cytoreductive surgery in the era of TMT.",

keywords = "Cytoreductive nephrectomy (CN), Kidney cancer, Targeted molecular therapy (TMT), Tyrosine kinase inhibitors (TKI)",

author = "Thomas, {Arun Z.} and Mehrad Adibi and Borregales, {Leonardo D.} and Karam, {Jose A.} and Wood, {Christopher G.}",

note = "Publisher Copyright: {\textcopyright} Translational Andrology and Urology.",

year = "2015",

doi = "10.3978/j.issn.2223-4683.2015.04.09",

language = "English (US)",

volume = "4",

pages = "301--309",

journal = "Translational Andrology and Urology",

issn = "2223-4683",

publisher = "AME Publishing Company",

number = "3",

}

TY - JOUR

T1 - Cytoreductive surgery in the era of targeted molecular therapy

AU - Thomas, Arun Z.

AU - Adibi, Mehrad

AU - Borregales, Leonardo D.

AU - Karam, Jose A.

AU - Wood, Christopher G.

N1 - Publisher Copyright: © Translational Andrology and Urology.

PY - 2015

Y1 - 2015

N2 - Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cell carcinoma (mRCC) in the immunotherapy era. With the advent of targeted molecular therapy (TMT) for the treatment of mRCC, the routine use of CN has been questioned. Up to date evidence continues to suggest that CN remains an integral part of treatment in appropriately selected patients. This review details the original context in which the efficacy of CN was established and rationale for the continued use of cytoreductive surgery in the era of TMT.

AB - Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cell carcinoma (mRCC) in the immunotherapy era. With the advent of targeted molecular therapy (TMT) for the treatment of mRCC, the routine use of CN has been questioned. Up to date evidence continues to suggest that CN remains an integral part of treatment in appropriately selected patients. This review details the original context in which the efficacy of CN was established and rationale for the continued use of cytoreductive surgery in the era of TMT.

KW - Cytoreductive nephrectomy (CN)

KW - Kidney cancer

KW - Targeted molecular therapy (TMT)

KW - Tyrosine kinase inhibitors (TKI)

UR - http://www.scopus.com/inward/record.url?scp=84934295152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934295152&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2223-4683.2015.04.09

DO - 10.3978/j.issn.2223-4683.2015.04.09

M3 - Review article

C2 - 26815334

AN - SCOPUS:84934295152

SN - 2223-4683

VL - 4

SP - 301

EP - 309

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

IS - 3

ER -

Cytoreductive surgery in the era of targeted molecular therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this